Our Tests


Also known as: MDM2 FISH, MDM2 amplification

« Back to test list


The MDM2 oncogene is located on the long arm of chromosome 12. Overexpression of this gene occurs in many types of cancer.

The overall frequency of MDM2 amplification in human tumours is 7%. The highest frequency is observed in soft tissue tumours (20%), osteosarcomas (16%) and oesophageal carcinomas (13%). This test has diagnostic implications.

Clinical Utility

In cases of unclear diagnosis, the presence of MDM2 gene amplification can be of assistance in distinguishing between (i) lipomas and atypical lipomatous tumour/well-differentiated liposarcomas, (ii) malignant undifferentiated tumours and dedifferentiated liposarcomas, and (iii) a variety of benign tumours and liposarcomas.

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.



Test Method

Fluorescent in situ hybridisation (FISH) analysis, using probes to the MDM2 gene.

Test Ordering

This test is usually requested by an oncologist.

Formalin fixed, paraffin-embedded tissue (FFPE) – 10 sections of 4 uM thickness, dried overnight at 37 degrees onto charged/coated slides.


Pricing note:

The price varies according to the specific clinical conditions for a particular patient. Please contact Sonic Genetics on 1800 010 447 for more information.

Medicare Rebate

This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.

Turnaround Time

2 working days.

For Doctors